|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-3-13
|
|
pubmed:abstractText |
Serial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
415-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
|
|
pubmed:publicationType |
Letter,
Comparative Study
|
